Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in China / NCT07764094
Recruiting Observational

Impact of Procedural Factors on Drug-Coated Balloon Outcomes in Coronary Artery Disease

NCT07764094 · tracked via the Priya Life Science China tracker
Sponsor
Nanjing First Hospital, Nanjing Medical University
Phase
Observational
Started
2026-09-01
Last updated
2026-08-28

Condition(s) studied

PCIDrug-coated BalloonCoronary Artery Disease

Study summary

This registry aimed to investigate drug-coated balloon procedural factors (particularly delivery time and inflation duration) to evaluate the impact on angiographic and clinical outcomes in patients undergoing percutaneous coronary intervention for de novo coronary lesions.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥18 years 2. Stable coronary artery disease or unstable angina 3. De novo coronary lesion (reference vessel diameter 2.25-4.0 mm; lesion length ≤40 mm) 4. Planned DCB strategy for PCI 5. Written informed consent Exclusion Criteria: 1. Acute myocardial infarction within 72 hours 2. Severe heart failure (NYHA class IV) 3. Severe hepatic or renal insufficiency 4. Allergy to drug-coated balloon components or antiplatelet agents, or intolerance to dual antiplatelet therapy 5. Life expectancy \<12 months 6. Pregnancy or breastfeeding 7. Concurrent participation in another clinical trial 8. In-stent restenosis 9. Unsuccessful recanalization of main vessel or side branch chronic total occlusion 10. Hemodynamic instability

Primary outcome measure(s)

  • Number of Participants with Target Lesion Restenosis — 6-12 months
    Percentage diameter stenosis at the target lesion as assessed by angiography at follow-up

Trial sites (7)

FacilityCityRegionStatus
Chuzhou First People's Hospital Chuzhou Anhui Recruiting
Tongling People's Hospital Tongling Anhui Recruiting
Huai'an Second People's Hospital Huai'an Jiangsu Recruiting
Lianyungang First People's Hospital Lianyungang Jiangsu Recruiting
Nanjing First Hospital Nanjing Jiangsu Recruiting
Xuzhou Second People's Hospital Xuzhou Jiangsu Recruiting
Yixing People's Hospital Yixing Jiangsu Recruiting

More Nanjing First Hospital, Nanjing Medical University trials in China

Research on Optimal Diagnosis and Treatment of Cardiorenal Syndrome Recruiting
IVUS-guided DK Crush Stenting Technique for Patients With Complex Bifurcation Lesions Active, not recruiting
Safety and Efficacy of DCB Therapy for de Novo Lesions Under the Guidance of QFR in CHD Patients (UNIQUE-DCB-I Study ) Starting soon
The Effect of Bupivacaine Liposome Preemptive Analgesia on Postoperative Pain and Delirium in Elderly Patients Undergoing Hip Fracture Surgery Starting soon
Characteristics of Papez Loop Neural Network in T2DM （Type 2 Diabetes Mellitus） Recruiting

Other trials for the same condition

IVUS-guided DK Crush Stenting Technique for Patients With Complex Bifurcation Lesions Active, not recruiting
SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes Recruiting
Prospective Study Protocol for Multiparametric PCCT Assessment of Early Ventricular Outcomes After CABG Recruiting
Prognosis and Antiplatelet Strategies for Patients With PCI and High Bleeding Risk:A Study Protocol Recruiting
Sedentary Behavior Intervention for Older Adults With Coronary Heart Disease and Frailty Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07764094 on ClinicalTrials.gov ↗ ← All trials in China